TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00942084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).
Study: NCT03667040

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JOOL app
Description: Participants will use the JOOL app for 30 days
Study: NCT01710787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: 3 unilateral intranasal sprays per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3%
Description: 3 unilateral intranasal sprays per dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 unilateral intranasal sprays per dose
Study: NCT01856816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Pattern Treatment B
Description: In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals.

Intervention type: OTHER
Group type: OTHER
Intervention: Meal Pattern Treatment C
Description: In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals.
Study: NCT01336686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: Arhalofenate 400 mg once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: Arhalofenate 600 mg once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Matching placebo once daily for 4 weeks
Study: NCT02737475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus vaccine
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPV-001 vaccine
Description: DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study: NCT03147352

Intervention type: DEVICE
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
Study: NCT02279667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: oral suspension 50 mg/mL
Study: NCT01311531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and fixation with TriMed fragment-specific system
Description: Anatomical reduction, achieved by the open technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and fixation with TriMed volar locking plate
Description: Anatomical reduction, achieved by the open technique.
Study: NCT02179580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiang-Sha-Liu-Jun-Zi-Tang
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiang-Sha-Liu-Jun-Zi-Tang
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
Study: NCT02765906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphic card
Description: A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics \& Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
Study: NCT00785252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered Intraosseous device (EZIO)
Description: EZIO

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard central line
Description: placement of a central line
Study: NCT04590482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
Study: NCT01298232

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Cardiophonogram
Description: Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Cardiophonogram
Description: Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
Study: NCT01868802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline at 0.9% intravenous infusion will be administered over 40 minutes.
Study: NCT04590482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
Study: NCT02409225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: no Home Monitoring
Description: Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
Study: NCT04121832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback training treatment in Fibromyalgia, a pilot study
Description: The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (treatment as usual)
Description: The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
Study: NCT02325206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: one administration in the morning
Study: NCT01336686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg colchicine daily for flare prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg colchicine daily for flare prophylaxis
Study: NCT02325206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one administration in the morning
Study: NCT02351297

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: casein supplementation
Description: After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein supplementation
Description: After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin supplementation
Description: After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
Study: NCT02279667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: oral suspension 50 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: oral suspension 50 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: 200 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: 200 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: 200 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: 800 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: 800 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: 800 mg tablet
Study: NCT03754348

Intervention type: RADIATION
Group type: OTHER
Intervention: PET scan with tracer injection [18F] DPA-714
Description: the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan with tracer injection [18F] DPA-714
Description: the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan with tracer injection [18F] DPA-714
Description: the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
Study: NCT03923634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Princess® RICH
Description: Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
Study: NCT00657163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: fluoxetine per os 20 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo per os daily
Study: NCT00692601

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute consumption of Capsiate Natura
Description: 10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute consumption of Capsiate Natura
Description: 10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute ingestion of identical placebo capsules
Description: 10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
Study: NCT04145739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
Study: NCT03223506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study: NCT01443676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be added to radiotherapy
Study: NCT03030469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in electronic health record default for new opioid analgesic prescriptions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in electronic health record default for new opioid analgesic prescriptions
Study: NCT01157247

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture
Study: NCT01443676

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy
Study: NCT01336686

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: 0.6 mg colchicine daily for flare prophylaxis
Study: NCT00607763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin (Mycamine)
Description: IV
Study: NCT03622775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study: NCT03843775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: encorafenib 450 mg oral QD
Study: NCT01241591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 690,550 5 mg
Description: CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 690,550 10 mg
Description: CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept 50 mg
Description: Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
Study: NCT03590158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRF
Description: Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
Study: NCT03547921

Intervention type: DEVICE
Intervention: iu22 ultrasound system - phillips
Description: iu22 ultrasound system - phillips

Intervention type: DEVICE
Intervention: iu22 ultrasound system - phillips
Description: iu22 ultrasound system - phillips
Study: NCT05174429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-Targeted Behavioral Activation
Description: The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence.
Study: NCT03315442

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Caffeine versus Energy Drink
Description: Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine versus Energy Drink
Description: Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
Study: NCT01245829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swabbing of observation chart
Description: The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Swabbing of observation chart
Description: The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
Study: NCT02189928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower limb tourniquet
Description: Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations').

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study: NCT02646566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04717323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mPAD (or TPAD) Pelvic Assist Device
Description: Gait retraining device that applies pelvic forces and measures response

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: Gait with no pelvic assistance
Study: NCT01686646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol + caffeine
Description: paracetamol with caffeine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol + caffeine
Description: paracetamol with caffeine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: paracetamol
Study: NCT02165930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
Study: NCT01157247

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture